Key result
CD28 T195P mutation linked to a non-significant trend toward shorter overall survival in AITL.
Why the study?
Angioimmunoblastic T-cell lymphoma is a rare aggressive lymphoma with known mutations, but novel recurrent mutations in CD28 have not been characterized.
Absolute Event Rate: 19.2% vs 45.2%
p-value: p=0.553
Frequent overlapping TET2, DNMT3A, and IDH2 mutations characterize AITL; leaves open mutation-stratified epigenetic therapy trials.
Angioimmunoblastic T-cell lymphoma (AITL) is a rare, aggressive type of T-cell lymphoma (TCL) that accounts for 18.5% of mature T-cell or natural killer (NK)-cell lymphomas.[1][1] Mutations in the IDH2, TET2 , and DNMT3A genes, frequently seen in various types of cancer, have also been linked to
No takes yet. Share an insight, caveat, or question.
Lee et al. (2015) conducted a letter in Angioimmunoblastic T-cell lymphoma (AITL) (n=125). CD28 T195P mutation vs. Wild-type CD28 (mutation-negative) was evaluated on Overall survival (months) (p=0.553). The CD28 T195P mutation was identified in 10.2% of AITL patients and was associated with a non-significant trend toward shorter overall survival (19.2 vs 45.2 months, P=0.553).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: